Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016-2025)
Abstract
Background: Immune checkpoint inhibitors (ICIs) are widely used in lung cancer treatment; however, immune-related adverse events (irAEs) remain an important safety-related research topic. Currently, there is a lack of comprehensive bibliometric analyses specifically addressing irAEs in lung cancer.
Methods: This study utilized the Web of Science Core Collection (WoSCC) and PubMed databases to retrieve literature on irAEs associated with ICIs in lung cancer from 2016 to 2025. Among the 1, 792 eligible records from WoSCC, bibliometric and visualization analyses were conducted using tools such as Bibliometrix and CiteSpace (v7.0). Meanwhile, PubMed records classified as clinical studies were used only for supplementary descriptive clinical-topic mapping, focusing on study types, disease settings, intervention regimens, and irAE-related topic categories.
Results: The results indicate that the annual publication volume in this field showed a continuous upward trend from 2016 to 2025, progressing through three distinct phases: the initial phase (2016-2019), the rapid increase phase (2020-2022), and the stable development phase (2023-2025);China ranked first globally with 626 publications, while the United States showed the highest betweenness betweenness centrality in the international collaboration network, suggesting a relatively strong bridging position; however, China's high publication output was not accompanied by a similarly high network betweenness centrality; co-citation…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.